Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: Results from the CLL8 trial Letter uri icon

Overview

MeSH Major

  • DNA Copy Number Variations
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Rituximab
  • Tumor Suppressor Protein p53

publication date

  • March 2017

Research

keywords

  • Letter

Identity

Digital Object Identifier (DOI)

  • 10.1038/leu.2016.317

PubMed ID

  • 27909343

Additional Document Info

start page

  • 734

end page

  • 738

volume

  • 31

number

  • 3